News
AstraZeneca’s COVID-19 vaccine,AZD 1222, is authorised for emergency supply in the UK.
AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released so that vaccinations may begin early in the New Year. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided authorisation for emergency supply of COVID-19 Vaccine AstraZeneca, formerly AZD 1222, for the active immunisation of individuals 18 years or older. The authorisation recommends two doses administered with an interval of between four and 12 weeks.
This regimen was shown in clinical trials to be safe and effective at preventing symptomatic COVID-19, with no severe cases and no hospitalisations more than 14 days after the second dose.
The MHRA’s decision was based on independent advice from its Commission on Human Medicines following a rolling review of trial data that included an interim analysis of the Phase III programme led by the University of Oxford. The data were also published in The Lancet on 8 December 2020. Additional safety and efficacy data for the vaccine will continue to accumulate from ongoing clinical trials.
Condition: Coronavirus/COVID-19 Infection
Type: drug